Medivir - Science working wonders

Improving life for cancer patients

Medivir is a pharmaceutical company focusing on the development of innovative treatments for cancer.

For those most in need

Medivir focuses on cancers of high unmet medical need to provide benefit to patients who so far have had few treatment options.

Our projects >

Partnering for breadth and depth

Medivir leverages collaborations with academic and industrial partners in order to bring specialty knowledge, experience and other capabilities to our projects.

Partnership >

Portfolio highlights

Fostroxacitabine bralpamide (fostrox)

Nucleotide DNA polymerase inhibitor (oral)

More about Fostroxacitabine bralpamide (fostrox)
View all our current projects

News

2024/06/28

Number of shares and votes in Medivir AB on 28 June 2024

Read more
2024/06/27

Fostrox + Lenvima® holds promise of greatly improved outcomes for advanced liver cancer patients, reveals new data from Medivir at ESMO GI

Read more
2024/06/19

Medivir selects global CRO partner for upcoming phase 2b study in HCC with fostrox + Lenvima and initiates study feasibility

Read more
See all

Partner with Medivir

Partnering is an important element of our business strategy. Together with our partners we have been successful in taking two products from research, through clinical development to launch on a global scale.

Read more